Through its four integrated service divisions, the Facility Maintenance and Operation Core (FAC-OPS) provides high containment operational management monitoring and oversight;routine facilities preventive maintenance and upkeep of the GNL physical plant that supports the entire facility including the high containment space and a preventative maintenance plan for all BSL4 equipment and systems;non-routine emergency repairs of BSL4 equipment and systems;and specialized training for facilities personnel working in and around BSL4 space and associated building systems. This core ensures continuous scientific support by combining management of base science support and high containment operational systems thus better maintaining synchrony with scientific program needs. Functional safety and security is ensured by independent oversight by autonomous entities from other cores that have supervisory responsibilities (biosafety, security, GMP&GLP compliance). The scientific, engineering and biosafety training activities within the GNL are interlinked with a succession of training experiences at increasing levels of biosafety for individuals with no previous experience within biocontainment. The progression of scientists and support staff through these levels is an important function of the training mission of the GNL which incorporates all levels of biosafety including BSL4. The amalgamation of science support, biocontainment and engineering services gives scientific and engineering staff increased opportunities to understand the integrated nature of such a facility and the importance of communication within the operational elements.
The Facility Maintenance and Operation Core provides high containment management and oversight, preventive maintenance and upkeep of the GNL physical plant, and specialized training for facilities personnel working in and around the BSL4 labs and associated systems. Operations and maintenance is closely coordinated with scientific program needs to ensure optimum support and maximum productivity.
|Gilchuk, Pavlo; Mire, Chad E; Geisbert, Joan B et al. (2018) Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates. J Infect Dis 218:S565-S573|
|Gilchuk, Pavlo; Kuzmina, Natalia; Ilinykh, Philipp A et al. (2018) Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein. Immunity 49:363-374.e10|
|Cross, Robert W; Mire, Chad E; Agans, Krystle N et al. (2018) Marburg and Ravn Viruses Fail to Cause Disease in the Domestic Ferret (Mustela putorius furo). J Infect Dis 218:S448-S452|
|Mire, Chad E; Geisbert, Joan B; Borisevich, Viktoriya et al. (2017) Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody. Sci Transl Med 9:|
|Thi, Emily P; Mire, Chad E; Lee, Amy Ch et al. (2017) siRNA rescues nonhuman primates from advanced Marburg and Ravn virus disease. J Clin Invest 127:4437-4448|
|Mire, Chad E; Cross, Robert W; Geisbert, Joan B et al. (2017) Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever. Nat Med 23:1146-1149|
|Warfield, Kelly L; Warren, Travis K; Qiu, Xiangguo et al. (2017) Assessment of the potential for host-targeted iminosugars UV-4 and UV-5 activity against filovirus infections in vitro and in vivo. Antiviral Res 138:22-31|
|Agrawal, Anurodh Shankar; Tao, Xinrong; Algaissi, Abdullah et al. (2016) Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccin Immunother 12:2351-6|
|Mire, Chad E; Geisbert, Thomas W; Feldmann, Heinz et al. (2016) Ebola virus vaccines - reality or fiction? Expert Rev Vaccines 15:1421-1430|
|Mire, Chad E; Geisbert, Joan B; Agans, Krystle N et al. (2016) Passive Immunotherapy: Assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates. J Infect Dis 214:S367-S374|
Showing the most recent 10 out of 59 publications